Company: VCYT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001384101-25-000051
Chunk: 53

Company: VERACYTE, INC.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 53
---
 Evaluating equity pay market analysis;
• Examining the change in control and severance arrangement; and

• Updating certain proxy disclosures, including this CD&A.

The Compensation Committee annually evaluates the independent compensation consultant’s independence and performance under the applicable SEC and Nasdaq listing standards. Aon and its affiliates did not provide any services to us other than the services described in this proxy statement relating to director and executive compensation. The Compensation Committee conducted a specific review of its relationship with Aon in 2024, pursuant to the SEC rules and Nasdaq listing standards, and concluded that Aon’s work for the Compensation Committee did not raise any conflicts of interest.

#### 50Veracyte2025 Proxy Statement

#### Executive Compensation

#### Use of Competitive Data
To assess the competitiveness of our executive compensation program and compensation levels, our Compensation Committee, with the assistance of Aon, examines the competitive compensation data for senior executives of our peer companies examining overall pay, and each pay element. The Compensation Committee uses a peer group to reference and analyze recent market data and understand the marketplace.

The Compensation Committee also considers other factors such as individual performance, experience, history and scope of responsibility, current market conditions and the specific needs of the business at critical points in time. The Compensation Committee uses its best business judgment in setting pay with the peer group data as a reference point rather than as specific benchmark or a specific formula for allocated pay across the various elements. The Compensation Committee conducts an annual assessment of the peer group to ensure that it reflects Veracyte’s most current financial and sector-specific standing.

#### 2024 Peer Group
Aon helped the Compensation Committee identify companies similar to us with respect to sector and market capitalization, as well as revenue and headcount, to provide a broad perspective on competitive pay levels and practices. The Compensation Committee also considers criteria from outside investors and the talent market when selecting the final criteria and list of companies. The following criteria were applied in developing the peer group used for 2024 compensation decisions:

• Sector - Biotechnology/Pharmaceuticals, Life Sciences Tools and Services, and Health Care Equipment & Supplies companies;

• Market Capitalization - $600.0 million to $5.6 billion, which was 0.3x to 3.0x; and

• Revenue - 0.5x to 3x Veracyte’s projected revenues.

Using these criteria, in July 2023 the following 18 companies were approved to make up our 2024 peer group^:

| 10